Syngene Partners with Johns Hopkins for Breakthrough Drug Discovery
Syngene International has partnered with Johns Hopkins University to accelerate early-stage drug discovery. Using Syngene SynVent, a comprehensive drug development platform, they aim to speed up translating research into viable therapies. This collaboration connects groundbreaking research with Syngene's capabilities to potentially revolutionize medicine development.
- Country:
- India
Syngene International has announced a strategic partnership with Johns Hopkins University, aiming to fast-track early-stage drug discovery.
The collaboration will leverage Syngene SynVent, a fully integrated platform that encompasses discovery biology, chemistry, and early drug development stages.
The partnership seeks to compress the timeline for new therapeutics by connecting Johns Hopkins' innovative research with Syngene's development expertise.
Advertisement
ALSO READ
-
Artificial intelligence could change future of antimicrobial drug discovery: Here's why
-
AI-driven drug discovery opens new path for natural product-based medicines
-
Health Hack 2026 to Drive Equitable Healthcare Innovations at VIT Bhopal University in Partnership with Johns Hopkins University
-
Syngene International's Q3 Profit Dips Amid Strategic Shifts
Google News